Revenue has remained near $1.4B to $1.6B while gross margin swung between roughly -6% and +7%, with the latest 1.6% operating margin suggesting a fragile recovery that warrants further investigation.
Agilon Health, Inc. (AGL) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Sales/Revenue | 6B | 5.93B | 6.06B | 4.32B | 2.39B | 1.52B | 1.22B | 794.41M |
| Revenue Growth % | 2.02% | -2.11% | 40.41% | 80.74% | 56.97% | 24.88% | 53.36% | - |
| Cost of Goods Sold | 5.84B | 6.12B | 6.06B | 4.25B | 2.28B | 1.46B | 1.12B | 765.9M |
| COGS % of Revenue | - | 103.18% | 99.92% | 98.39% | 95.34% | 95.68% | 92.27% | 96.41% |
| Gross Profit | 165.71M | -188.61M | 4.84M | 69.67M | 111.36M | 65.74M | 94.15M | 28.51M |
| Gross Margin % | 2.76% | -3.18% | 0.08% | 1.61% | 4.66% | 4.32% | 7.73% | 3.59% |
| Gross Profit Growth % | - | -3996.2% | -93.05% | -37.44% | 69.38% | -30.17% | 230.22% | - |
| Operating Expenses | 275.48M | 232.46M | 296.97M | 301.8M | 216.74M | 437.99M | 150.82M | 135.09M |
| OpEx % of Revenue | - | 3.92% | 4.9% | 6.99% | 9.08% | 28.79% | 12.38% | 17% |
| Selling, General & Admin | 269.97M | 238.54M | 268.91M | 285.76M | 207.79M | 427.5M | 137.29M | 122.83M |
| SG&A % of Revenue | - | 4.02% | 4.44% | 6.62% | 8.7% | 28.1% | 11.27% | 15.46% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -6.08M | 28.06M | 16.04M | 8.95M | 10.48M | 13.53M | 12.25M |
| Operating Income | -109.77M | -421.08M | -292.13M | -232.13M | -105.38M | -372.24M | -56.67M | -106.57M |
| Operating Margin % | -1.83% | -7.1% | -4.82% | -5.38% | -4.41% | -24.47% | -4.65% | -13.42% |
| Operating Income Growth % | - | -44.14% | -25.85% | -120.29% | 71.69% | -556.82% | 46.82% | - |
| EBITDA | -82.41M | -392.48M | -267.67M | -211.97M | -91.61M | -357.57M | -42.57M | -65.16M |
| EBITDA Margin % | -1.37% | -6.62% | -4.42% | -4.91% | -3.84% | -23.5% | -3.49% | -8.2% |
| EBITDA Growth % | 76.41% | -46.63% | -26.27% | -131.4% | 74.38% | -739.88% | 34.66% | - |
| D&A (Non-Cash Add-back) | 27.36M | 28.59M | 24.46M | 20.16M | 13.77M | 14.67M | 14.1M | 41.41M |
| EBIT | -112.7M | -397.45M | -242.65M | -187.8M | -86.19M | -376.83M | -54.21M | -105.62M |
| Net Interest Income | -3.26M | -6.64M | -6.18M | -6.66M | -4.48M | -6.15M | -8.13M | -9.07M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.26M | 6.64M | 6.18M | 6.66M | 4.48M | 6.15M | 8.13M | 9.07M |
| Other Income/Expense | 8.64M | 16.98M | 43.3M | 37.67M | 14.71M | -10.73M | -5.67M | -8.11M |
| Pretax Income | -101.12M | -404.1M | -248.83M | -194.46M | -90.67M | -382.98M | -62.34M | -114.69M |
| Pretax Margin % | -1.68% | -6.81% | -4.11% | -4.51% | -3.8% | -25.17% | -5.12% | -14.44% |
| Income Tax | 4.92M | 1.25M | 1.45M | 791K | 1.64M | 886K | 865K | -232K |
| Effective Tax Rate % | -4.86% | -0.31% | -0.58% | -0.41% | -1.81% | -0.23% | -1.39% | 0.2% |
| Net Income | -106.04M | -405.35M | -260.15M | -262.6M | -106.55M | -406.49M | -60.05M | -282.59M |
| Net Margin % | -1.77% | -6.83% | -4.29% | -6.08% | -4.46% | -26.72% | -4.93% | -35.57% |
| Net Income Growth % | 65.6% | -55.81% | 0.93% | -146.45% | 73.79% | -576.89% | 78.75% | - |
| Net Income (Continuing) | -106.04M | -405.35M | -250.28M | -195.25M | -92.31M | -383.86M | -63.21M | -114.45M |
| Discontinued Operations | 0 | 0 | -9.82M | -67.55M | -14.55M | -22.93M | 3.16M | 0 |
| Minority Interest | 0 | 0 | 0 | -818K | -611K | -300K | 0 | 0 |
| EPS (Diluted) | -6.00 | -24.50 | -15.75 | -16.00 | -6.50 | -27.25 | -4.00 | -18.50 |
| EPS Growth % | 64.32% | -55.56% | 1.56% | -146.15% | 76.15% | -581.25% | 78.38% | - |
| EPS (Basic) | - | -24.50 | -15.75 | -16.00 | -6.50 | -27.25 | -4.00 | -18.50 |
| Diluted Shares Outstanding | 17.69M | 16.56M | 16.44M | 16.36M | 16.33M | 14.92M | 15.39M | 15.36M |
| Basic Shares Outstanding | 16.79M | 16.56M | 16.44M | 16.36M | 16.33M | 14.92M | 15.39M | 15.36M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying AGL stock.
For fiscal year 2025, Agilon Health, Inc. (AGL) reported total revenue of $5.93B. This represents a 646.8% increase compared to $794.4M in 2019.
Agilon Health, Inc. (AGL) reported a net loss of $405.3M for the fiscal year ending 2025.
Agilon Health, Inc. (AGL) reported an operating income of $-421.1M, resulting in an operating profit margin of -7.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Agilon Health, Inc. (AGL) generated $-188.6M in gross profit for the year, representing a gross profit margin of -3.2%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent negative gross margins
Metrics are mathematically derived from official filings.
Revenue Stabilizing After Volatile Stretch
Based on AGL's reported quarterly figures, revenue has held near $1.4B to $1.6B across the ten quarters, with the latest quarter showing a 5.9% sequential-style growth signal that remains insufficient to confirm a durable reacceleration in the top line.
The revenue base has been essentially flat in absolute terms, suggesting membership growth is being offset by per-member economics or attrition. The year-over-year change of -2.1% points to contraction at the consolidated level, while the most recent quarter's uptick may reflect favorable seasonality or risk-adjustment timing rather than a structural shift. Investors should monitor whether membership and risk-adjusted revenue per member move in the same direction before treating this as a trend.
Gross Margin Recovery Remains Fragile
As reported in AGL's income statement, gross margin has swung between roughly -6% and +7% across recent quarters, with the most recent print of 6.4% suggesting improvement but not yet evidence of stable unit economics.
The move from deeply negative gross profit in late 2025 to positive territory in 2026 is directionally encouraging, yet the margin has been volatile enough that a single quarter should not be extrapolated. Medical cost ratios appear to be the dominant swing factor, and the gap between capitation revenue and claims expense remains narrow. The question for analysts is whether recent gains reflect sustained utilization control or timing effects in claims recognition.
Overhead Absorbs Most Gross Profit Gains
Based on AGL's reported figures, SG&A of roughly $54M to $88M per quarter consumes most of the gross profit generated, leaving operating margin at just 1.6% in the latest quarter despite the recovery in gross margin.
Operating income has moved more sharply than gross profit in both directions, indicating high fixed overhead relative to the earnings base. The latest quarter shows some positive operating leverage, but SG&A has not declined meaningfully as a share of revenue. Scaling efficiency will depend on whether overhead growth remains decoupled from membership growth over the coming periods.
EPS Swings Overstate Underlying Progress
According to reported results, AGL's diluted EPS moved from losses near -$11.50 in late 2025 to $1.97 in the latest quarter, a swing large enough that the share count and non-operating items likely deserve close scrutiny before drawing conclusions.
Net income has at times diverged meaningfully from operating income, and the magnitude of EPS swings relative to revenue suggests sensitivity to prior-period claim adjustments and possible tax effects. Stock-based compensation, while modest at $6M to $24M per quarter, remains a recurring cost that adds to dilution pressure. Investors should treat recent profitability as provisional until the consistency of net income with operating results is demonstrated over more periods.
Margin Recovery May Prove Temporary
The strongest challenge to the current narrative is that AGL's recent positive margins may reflect timing of medical cost recognition rather than durable improvement, given a history of sharp reversals across the ten-quarter window.
Negative revenue growth on a year-over-year basis, combined with persistent operating losses in much of the period, suggests the business has not yet proven it can scale profitably. Concentration risk in a few states and dependence on annual risk-adjustment outcomes could compress revenue abruptly if regulatory conditions shift. Analysts may wish to weight the trailing period heavily until several consecutive quarters of positive gross and operating margin are reported.